Skip to content

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06434337
Enrollment
600
Registered
2024-05-30
Start date
2024-07-23
Completion date
2028-03-31
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papillomavirus

Brief summary

To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.

Detailed description

Primary Objectives 1\. To evaluate the performance of 3 versions of a novel point-of-care diagnostic test for detecting HPV ("Rice HPV test"). Secondary Objectives 1. To evaluate the results of the Rice HPV test with corresponding pathology results to assess the association of HPV test results with the presence of high-grade cervical dysplasia (CIN 2+). 2. To assess how different sample processing methods affect the performance of the Rice HPV test. 3. To assess how different test readout methods affect the performance of the Rice HPV test. Exploratory Objectives 1. Compare the performance of the Rice HPV test between provider-collected and self-collected samples. 2. Conduct a survey on participant experiences with self-sampling to assess whether participants prefer self-sampling over provider-collected sampling. 3. Compare the performance of the Rice HPV test to other benchmark HPV tests such as GeneXpert.

Interventions

DIAGNOSTIC_TESTNovel point-of-care diagnostic test for detecting HPV ("Rice HPV test")

Given by Diagnostic Test

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. People with a cervix 21 years of age or older. 2. Scheduled to undergo hrHPV testing at MD Anderson and The Harris Health System (LBJ Hospital) according to national and institutional guidelines at time of enrollment OR are anticipated to undergo a LEEP, ECC, or biopsy. 3. Willing and able to provide informed consent. 4. Able to perform protocol-required activities. Able to speak and read English or Spanish.

Exclusion criteria

1. Patient or provider decision not to perform HPV testing. This does not apply to patients that are undergoing either a LEEP, ECC or biopsy. 2. Participant or provider decision not to collect a sample for this study. 3. Participants that are pregnant.

Design outcomes

Primary

MeasureTime frameDescription
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")Through study completion; an average of 1 yearTo evaluate the performance of the 3 version of a novel point-of-care diagnostic test for detecting HPV ("Rice HPV test").

Countries

United States

Contacts

CONTACTKathleen Schmeler, MD
kschmele@mdanderson.org(713) 745-3518
PRINCIPAL_INVESTIGATORKathleen Schmeler, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026